ABS 0871
Alternative Names: ABS-0871Latest Information Update: 07 Feb 2025
At a glance
- Originator Actio Biosciences
- Class Small molecules
- Mechanism of Action TRPV4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Charcot-Marie-Tooth disease type 2C
- Preclinical Bone disorders
- Research Overactive bladder
Most Recent Events
- 07 Feb 2025 Early research in Overactive bladder in USA (PO), (Actio Biosciences pipeline, February 2025)
- 07 Feb 2025 Phase-I clinical trials in Charcot-Marie-Tooth disease type-2C (In volunteers) (PO), prior to February 2025 (Actio Biosciences pipeline, February 2025)
- 25 Sep 2024 Actio Biosciences plans a phase I clinical trial for Charcot-Marie-Tooth disease and bone disorders by year-end 2024